For UK MedTech companies
Your MedTech product works, but NHS procurement keeps it off the list
Fragmented trust requirements, opaque frameworks, and resource-heavy tender processes mean genuinely effective solutions routinely fail to reach patients. Many MedTech companies have already walked away from NHS tenders they could not afford to navigate.
Two minutes. Solva follows up with specific approved supplier list options.
- Innovative MedTech solutions remain stuck in pilot phases without widespread adoption across the NHS.
- SMEs spend disproportionate resources on tender applications with low success rates.
- NHS patients miss out on access to potentially life-changing or efficiency-enhancing technologies.
- MedTech companies prioritize other international markets with clearer and faster market access pathways.
- Delayed adoption of efficiency-enhancing technologies, leading to continued manual processes and staff burden.
- Inconsistent availability of advanced medical devices across NHS trusts, impacting service delivery.
- NHS misses out on long-term cost savings from innovative MedTech solutions, potentially leading to higher overall healthcare expenditure.
- MedTech SMEs experience significant revenue loss and reduced investment in UK-specific R&D due to market access barriers.
- Delayed patient access to innovative diagnostic tools and treatments, potentially impacting health outcomes.
- Variations in care quality and availability of advanced medical interventions across different NHS regions.
- NHS perceived as slow to adopt innovation, impacting its attractiveness as a partner for global MedTech companies.
- Negative perception among MedTech innovators, potentially leading to a brain drain of talent and investment from the UK.
The NHS spends around £10 billion a year on medical technology (GOV.UK, 2023)
Source: https://www.gov.uk/government/news/new-strategy-to-boost-nhs-access-to-innovative-medical-technology
Frequently asked questions
Why does this problem persist?
The NHS procurement landscape is complex and fragmented, with multiple entry points and varying requirements across trusts. MedTech SMEs often lack the dedicated resources and expertise to successfully tender for contracts and meet the stringent criteria for approved supplier status, leading to significant delays or outright exclusion.
What is the cost of leaving it unaddressed?
Over a third of MedTech companies have chosen not to bid on specific NHS tenders due to unworkable requirements (ABHI, 2023)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.